DE3853365T2 - Verwendung von sulfatierten zuckern. - Google Patents

Verwendung von sulfatierten zuckern.

Info

Publication number
DE3853365T2
DE3853365T2 DE3853365T DE3853365T DE3853365T2 DE 3853365 T2 DE3853365 T2 DE 3853365T2 DE 3853365 T DE3853365 T DE 3853365T DE 3853365 T DE3853365 T DE 3853365T DE 3853365 T2 DE3853365 T2 DE 3853365T2
Authority
DE
Germany
Prior art keywords
caused
microbial
inflammation
tissue
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3853365T
Other languages
English (en)
Other versions
DE3853365D1 (de
Inventor
Daniel Bar-Shalom
Niels Bukh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Buhk Meditec AS
Original Assignee
Buhk Meditec AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK674087A external-priority patent/DK674087D0/da
Application filed by Buhk Meditec AS filed Critical Buhk Meditec AS
Application granted granted Critical
Publication of DE3853365D1 publication Critical patent/DE3853365D1/de
Publication of DE3853365T2 publication Critical patent/DE3853365T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/26—Aluminium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/58—Metal complex; Coordination compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Seasonings (AREA)
  • Polymerisation Methods In General (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE3853365T 1987-12-21 1988-12-21 Verwendung von sulfatierten zuckern. Expired - Fee Related DE3853365T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK674087A DK674087D0 (da) 1987-12-21 1987-12-21 Saarbehandlingsmiddel
DK505488A DK505488D0 (da) 1987-12-21 1988-09-09 Middel og anvendelse af samme
PCT/DK1988/000217 WO1989005646A1 (en) 1987-12-21 1988-12-21 Uses of sulphated sugars

Publications (2)

Publication Number Publication Date
DE3853365D1 DE3853365D1 (de) 1995-04-20
DE3853365T2 true DE3853365T2 (de) 1995-07-27

Family

ID=26067713

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3853365T Expired - Fee Related DE3853365T2 (de) 1987-12-21 1988-12-21 Verwendung von sulfatierten zuckern.
DE3856442T Expired - Fee Related DE3856442T2 (de) 1987-12-21 1988-12-21 Verwendung von sulfatierten Zuckern gegen Entzundung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE3856442T Expired - Fee Related DE3856442T2 (de) 1987-12-21 1988-12-21 Verwendung von sulfatierten Zuckern gegen Entzundung

Country Status (9)

Country Link
EP (3) EP0420849A1 (de)
JP (2) JPH04500797A (de)
KR (2) KR930003117B1 (de)
AT (2) ATE119778T1 (de)
AU (2) AU2914589A (de)
DE (2) DE3853365T2 (de)
DK (4) DK505488D0 (de)
HK (1) HK56396A (de)
WO (2) WO1989005646A1 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK674087D0 (da) * 1987-12-21 1987-12-21 Bar Shalom Daniel Saarbehandlingsmiddel
DK505488D0 (da) * 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme
US5202311A (en) * 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
US5618798A (en) * 1989-04-20 1997-04-08 Bar-Shalom; Daniel Use of sucralfate to treat baldness
IT1230157B (it) * 1989-06-16 1991-10-14 Lisapharma Spa Uso di sucralfato gel umido per il trattamento di ulcere del derma e come veicolo di farmaci ad attivita' topica
IL95642A0 (en) * 1989-09-15 1991-06-30 Pehrom Pharmaceutical Corp Topical preparations for treatment of ulcers and other lesions
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
CA2090479C (en) * 1990-08-31 2002-01-15 Kiyoshige Ochi Stock solution of sucralfate suspended in water and production thereof
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
EP0509120B1 (de) * 1991-04-18 1996-07-17 LABORATORI BALDACCI Spa Topische Anwendung von Glycosaminoglykane zur Prävention und Behandlung der Zervikal- oder Vaginalerkrankungen
US5990095A (en) * 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
IT1251151B (it) * 1991-08-05 1995-05-04 Fidia Spa Materiale spugnoso essenzialmente costituito da acido ialuronico,o suoi derivati
US6147059A (en) * 1992-02-20 2000-11-14 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6114314A (en) * 1992-02-21 2000-09-05 Hyal Pharmaceutical Corp. Formulations containing hyaluronic acid
US5457128A (en) * 1992-03-28 1995-10-10 Dott Limited Company Topical preparation for healing wounds of the skin
US6750207B1 (en) * 1992-05-01 2004-06-15 Yeda Research And Development Co. Ltd. Compositions for the regulation of cytokine activity
DK86492D0 (da) * 1992-06-30 1992-06-30 Bukh Meditec Laegemiddel
WO1994020115A2 (en) * 1993-03-10 1994-09-15 Miles, Inc. Hyaluronic acid used as a cancer treatment
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
EP0691844A1 (de) * 1993-03-29 1996-01-17 Queen's University At Kingston Verfahren zur behandlung von amyloidosis
US5434144A (en) * 1994-03-04 1995-07-18 The Procter & Gamble Company Methods of using cyclic polyanionic polyol derivatives for regulating skin wrinkles
DE69533724T2 (de) * 1994-03-28 2005-10-27 The Trustees Of Columbia University In The City Of New York Zusammensetzung zum inaktivieren von reizstoffen in flüssigkeiten
KR100264547B1 (ko) * 1994-04-26 2000-12-01 나가야마 오사무 수크랄페이트의용융조립제제및그의제조방법
SE9401826D0 (sv) * 1994-05-27 1994-05-27 Pharmacia Ab Anti-Helicobacter pyroli substance
US5783568A (en) * 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
WO1996023507A1 (fr) * 1995-02-02 1996-08-08 Chugai Seiyaku Kabushiki Kaisha Preparation de sucralfate
WO1996024362A1 (fr) * 1995-02-07 1996-08-15 Shiseido Company, Ltd. Agents anti-inflammatoires
CN1196734A (zh) * 1995-09-19 1998-10-21 生化学工业株式会社 消炎药
JP3263598B2 (ja) * 1995-11-01 2002-03-04 有限会社ドット 経鼻吸収用生理活性ペプチド組成物
US5837266A (en) * 1996-04-30 1998-11-17 Hydromer, Inc. Composition, barrier film, and method for preventing contact dermatitis
CH690719A5 (it) * 1996-08-19 2000-12-29 Rotta Res B V Amsterdam Swiss Procedimento per la preparazione di sali misti della glucosamina.
AU4995597A (en) * 1996-10-23 1998-05-15 Vertex Pharmaceuticals Incorporated Methods of using sucrose octasulfate to treat or prevent enveloped virus infection
GB9625193D0 (en) 1996-12-04 1997-01-22 Ml Lab Plc Treatment of highly vascular tumours
WO1999026636A1 (fr) * 1997-11-24 1999-06-03 Zhongming Zeng Formulation pharmaceutique de stimulation de la croissance de bacilles gram positifs et d'augmentation de l'acidite du vagin et leur utilisation
FI974321A0 (fi) 1997-11-25 1997-11-25 Jenny Ja Antti Wihurin Rahasto Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa
AU2798299A (en) * 1998-02-27 1999-09-15 Althexis Company, The Therapeutic and prophylactic uses of negatively charged substituted disaccharides
US5902800A (en) * 1998-03-27 1999-05-11 Glenpharma Dextran formulations and method for treatment of inflammatory joint disorders
US7906153B2 (en) 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
BR9806540C1 (pt) * 1998-06-09 2001-05-08 Akira Yoshitome Produto farmacêutico para tratamento de hemofilia e de bronquite asmática
AU2007200916B2 (en) * 1998-10-05 2009-09-17 Kabushiki Kaisha Yakult Honsha Antibacterial agents and process for producing the same
EP1120100B1 (de) * 1998-10-05 2005-08-17 Kabushiki Kaisha Yakult Honsha Antibakterielle mittel und ein herstellungsverfahren dafür
JP2002532520A (ja) * 1998-12-22 2002-10-02 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 気道病治療および気道用薬剤送達のための化合物および方法
US6964949B2 (en) 2000-05-24 2005-11-15 Shanghai Jiao Da Onlly Co., Ltd. Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in the vagina and the use thereof
BRPI0101486B1 (pt) * 2001-04-17 2017-09-19 Cristália Produtos Químicos Farmacêuticos Ltda. Pharmaceutical composition for topic use containing heparin for the treatment of skin or mucosal injuries caused by burns
US7285536B2 (en) 2001-12-05 2007-10-23 Yeda Research And Development Co., Ltd. Anti-cancer therapeutic compounds
DE10161149B4 (de) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum
EP1462099A4 (de) * 2001-12-13 2007-12-26 Dia Pharmaceutical Co Ltd Gelzusammensetzungen zur äusseren anwendung, polstermaterialien und in blisterpackungen einzupackende polstermaterialien
US7879365B2 (en) 2002-02-07 2011-02-01 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation
EP1480517A4 (de) 2002-02-07 2007-08-22 Univ Columbia Zinksalzzusammensetzungen für die vorbeugung von schleimhautreizung durch spermizide und mikrobizide
US7265097B2 (en) 2002-08-20 2007-09-04 Chitogenics, Inc. Methods of drug delivery using sulphated chitinous polymers
US20060234977A1 (en) * 2003-01-23 2006-10-19 Gina Wenham Antiviral compostion comprising a sulphated glucose polymer and a bacteriostatic agent
CN101217870B (zh) 2003-07-17 2011-10-12 纽约市哥伦比亚大学托管会 含有季铵化合物及精油和/或精油成分的协同组合的抗微生物组合物
US20080249165A1 (en) * 2004-08-05 2008-10-09 Ivax Drug Research Institute Ltd. Glycosides and Salts Thereof
JP5164572B2 (ja) * 2004-08-05 2013-03-21 アイバックス ドラッグ リサーチ インスティテュート エルティーディー． 多硫酸化グリコシド及びその塩
WO2006017752A2 (en) * 2004-08-05 2006-02-16 Ivax Corporation Sulfated oligosaccharides
US8044100B2 (en) 2004-12-22 2011-10-25 Bellus Health Inc. Methods and compositions for treating amyloid-related diseases
ATE404209T1 (de) * 2005-09-16 2008-08-15 Italfar Societa A Responsabili Wundheilende pharmazeutische zusammensetzung enthaltend sucralfat, glycin, aluminium acetat und vitamine
ATE481094T1 (de) 2005-12-22 2010-10-15 Kiacta Sarl Behandlung von diabetischer nephropathie
KR20080025900A (ko) * 2006-09-19 2008-03-24 (주) 서울바이오메드 글루코사민 또는 글루코사민 유도체를 포함하는 알레르기성결막염 치료용 조성물 및 이를 사용하여 알레르기성결막염을 치료하는 방법
CN103787927B (zh) 2006-10-12 2017-03-01 Bhi有限合资公司 递送3‑氨基‑1‑丙磺酸的方法、化合物、组合物和载体
GB0622688D0 (en) 2006-11-14 2006-12-27 Diosamine Dev Corp Novel compounds
GB2450087A (en) * 2007-06-11 2008-12-17 Diosamine Dev Corp Use of sulphated saccharides in the treatment of inflammatory and/or auto-immune diseases
CA2736884A1 (en) 2008-09-17 2010-03-25 Patrick D. Mcgrath Antimicrobial sucralfate paste methods and compositions
ES2507495T3 (es) * 2008-11-20 2014-10-15 Laboratori Derivati Organici S.P.A. Uso de sulfato de heparano en preparaciones cosmetológicas y dermatológicas
FR2953522B1 (fr) * 2009-12-07 2012-03-09 Fabre Pierre Dermo Cosmetique Sucrose octasulfates de zinc, leur preparation et leurs applications pharmaceutiques et cosmetiques
FR2956322A1 (fr) * 2010-02-17 2011-08-19 Urgo Lab Utilisation d'oligosaccharides polysulfates synthetiques comme agents de detersion d'une plaie.
WO2011109469A1 (en) * 2010-03-03 2011-09-09 Neocutis Sa Compositions and methods for treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds
JP2014501730A (ja) * 2010-12-01 2014-01-23 ジ オーストラリアン ナショナル ユニバーシティ ヒストン阻害
ITMI20110033A1 (it) * 2011-01-17 2012-07-18 Biofarmitalia Spa Composizione terapeutica mucoadesiva a base di acido ialuronico per la prevenzione e terapia di lesioni epiteliali, delle mucose del corpo umano
FR2975993B1 (fr) * 2011-05-31 2013-06-28 Fabre Pierre Dermo Cosmetique Sucroses octasulfates de magnesium, leur preparation et leurs applications pharmaceutiques et cosmetiques
FR2975994B1 (fr) * 2011-05-31 2015-03-06 Fabre Pierre Dermo Cosmetique Sucroses octasulfates de calcium, leur preparation et leurs applications pharmaceutiques et cosmetiques
FR2991876B1 (fr) * 2012-06-13 2014-11-21 Vivacy Lab Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
FR2993182B1 (fr) 2012-07-13 2014-10-17 Urgo Lab Pansement a liberation prolongee d'actifs
WO2014151565A1 (en) 2013-03-15 2014-09-25 The Brigham And Women's Hospital, Inc. Compounds to modulate intestinal absorption of nutrients
KR101649201B1 (ko) * 2014-01-22 2016-08-18 대구가톨릭대학교산학협력단 오만둥이 유래 황산다당을 유효성분으로 함유하는 피부 미백 및 주름 개선용 화장료 조성물
WO2017053970A1 (en) 2015-09-24 2017-03-30 The Brigham And Women's Hospital, Inc. Water-activated mucoadhesive compositions to reduce intestinal absorption of nutrients
FR3043556B1 (fr) * 2015-11-17 2020-01-10 Urgo Recherche Innovation Et Developpement Utilisation de composes oligosaccharidiques pour activer l'angiogenese
FR3044555B1 (fr) 2015-12-07 2020-03-06 Centre National De La Recherche Scientifique - Cnrs - Film comprenant un oligosaccharide polysulfate et un polycation et son procede de fabrication
FR3060392B1 (fr) * 2016-12-19 2019-07-12 Urgo Recherche Innovation Et Developpement Utilisation de composes oligosaccharidiques pour activer l'epidermisation
IT201700047632A1 (it) * 2017-05-03 2018-11-03 Ricerfarma Srl Composizioni topiche per mantenere e ripristinare l'omeostasi idrica della pelle

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486416A (en) * 1981-03-02 1984-12-04 Soll David B Protection of human and animal cells subject to exposure to trauma
FR2503563A1 (fr) * 1981-04-09 1982-10-15 Pos Lab Composition pour collyre a base de sulfate de chondroitine a
DE3131811A1 (de) * 1981-08-12 1983-04-21 Serapharm - Michael Stroetmann, 4400 Münster Heparinsalbe zur percutanen behandlung von thrombophlebitiden oder varizen
IT1189298B (it) * 1982-06-18 1988-02-04 Manetti & Roberts Italo Brit Procedimento per produrre i glicosa minoglicani dermatansolfato ed eparan-solfato sostanzialmente puri e loro impiego farmaceutico
JPS5978116A (ja) * 1982-10-27 1984-05-04 Chugai Pharmaceut Co Ltd スクラルフェ−ト製剤
US4640912A (en) * 1983-06-09 1987-02-03 Hausman Marvin S Administration of "active" chondroitin sulfate A and "active" chondroitin sulfate C or mixtures thereof to mammals including humans
DE3323389A1 (de) * 1983-06-29 1985-01-10 B. Braun Melsungen Ag, 3508 Melsungen Auf schleimhaeute des mundes, der nase und/oder des rachens wirkende arzneimittel auf der basis von heparin und tensiden
AU555747B2 (en) * 1983-08-09 1986-10-09 Cilco Inc. Chondroitin sulfate and sodium hyaluronate composition
CA1218601A (en) * 1983-09-02 1987-03-03 Angel B. Casillan Sucralfate suspension
AU607690B2 (en) * 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
DK164199C (da) * 1986-05-16 1992-10-19 Chugai Pharmaceutical Co Ltd Sucralfatpraeparat til anvendelse paa oesophagus mucosa
EP0254845A3 (de) * 1986-06-10 1989-04-19 Lescarden Inc. Immun-Stimulation mit Chondroitin-sulfat
DK505488D0 (da) * 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme

Also Published As

Publication number Publication date
KR900700109A (ko) 1990-08-11
AU631529B2 (en) 1992-12-03
EP0394333B1 (de) 1995-03-15
AU2914689A (en) 1989-07-19
EP0420849A1 (de) 1991-04-10
DE3856442D1 (de) 2000-12-21
DK5792D0 (da) 1992-01-17
WO1989005646A1 (en) 1989-06-29
KR930003117B1 (ko) 1993-04-19
DK151590A (da) 1990-08-14
DK151590D0 (da) 1990-06-21
EP0640346A1 (de) 1995-03-01
WO1989005645A1 (en) 1989-06-29
DK5792A (da) 1992-01-17
JPH04500798A (ja) 1992-02-13
DK151690D0 (da) 1990-06-21
AU2914589A (en) 1989-07-19
EP0394333A1 (de) 1990-10-31
DK165357B (da) 1992-11-16
KR900700108A (ko) 1990-08-11
EP0640346B1 (de) 2000-11-15
ATE197546T1 (de) 2000-12-15
ATE119778T1 (de) 1995-04-15
JPH0739347B2 (ja) 1995-05-01
HK56396A (en) 1996-04-03
DK165357C (da) 1993-04-05
DK505488D0 (da) 1988-09-09
DK151690A (da) 1990-08-15
JPH04500797A (ja) 1992-02-13
DE3856442T2 (de) 2001-05-10
DE3853365D1 (de) 1995-04-20
DK169018B1 (da) 1994-08-01

Similar Documents

Publication Publication Date Title
DE3853365T2 (de) Verwendung von sulfatierten zuckern.
Grimes Psoralen photochemotherapy for vitiligo
Waghmare Radiation burn—from mechanism to management
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
Schindl et al. Low intensity laser irradiation in the treatment of recalcitrant radiation ulcers in patients with breast cancer–long‐term results of 3 cases
ES2033021T3 (es) Agente con efecto destructivo a tumores malignos, procedimiento para su obtencion y preparacion para la aplicacion en la terapia de enfermos de cancer.
Chernosky et al. Squamous cell carcinoma in lesions of disseminated superficial actinic porokeratosis: a report of two cases
RU2495689C2 (ru) Способ лечения подострых и хронических неспецифических цервицитов нерожавшим женщинам, включающий курс лазерного фотофореза с применением бальнеологического средства "эльтон"-гель
Rivers et al. No effect of topical tretinoin on lentigo maligna
CA2020199A1 (en) Uses of sulphated sugars
Cohen et al. Cornifying Darier disease—A unique variant: II. Surgical treatment
De Moragas et al. 5-Fluorouracil ointment in tumors of the skin
RU2233184C2 (ru) Способ лечения острого сальпингоофорита
Romig et al. Facial sporotrichosis during pregnancy: A therapeutic dilemma
RU2566201C1 (ru) Способ лечения витилиго
Lucky Acquired bromhidrosis in an 8-year-old boy secondary to a nasal foreign body
Sonam et al. Management of Mashaka (Elevated Mole) and Tilkalaka (Non-elevated Mole) by Agnikarma–A case report
Higa et al. Actinic keratosis and capecitabine therapy
Shierholz et al. Pyometra complicating radiation therapy of uterine malignancy
GREENHOUSE Trichophyton violaceum infection of scalp and glabrous skin of an adult
JP2527757B2 (ja) 皮膚の炎症を減少させる化合物およびその組成物
Cho et al. Topical Methyl Aminolevulinate Photodynamic Therapy in Porokeratosis of Mibelli: An Alternative Treatment for a Refractory Disease
Bhushan et al. Dermatological disorders presenting in deeply pigmented skin
Smyczek-Gargya et al. Pseudolymphoma of the nipple
Oster-Schmidt et al. Successful Treatment of Basal Cell Carcinoma on the Face with Imiquimod 5% Cream.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee